HRP20180064T1 - Cjepiva s kapsularnim biokonjugatima iz gram-pozitivnih bakterija - Google Patents
Cjepiva s kapsularnim biokonjugatima iz gram-pozitivnih bakterija Download PDFInfo
- Publication number
- HRP20180064T1 HRP20180064T1 HRP20180064TT HRP20180064T HRP20180064T1 HR P20180064 T1 HRP20180064 T1 HR P20180064T1 HR P20180064T T HRP20180064T T HR P20180064TT HR P20180064 T HRP20180064 T HR P20180064T HR P20180064 T1 HRP20180064 T1 HR P20180064T1
- Authority
- HR
- Croatia
- Prior art keywords
- staphylococcus aureus
- bacterium
- bacteria
- gram
- prokaryotic organism
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33217010P | 2010-05-06 | 2010-05-06 | |
| EP11724567.0A EP2566507B1 (en) | 2010-05-06 | 2011-05-04 | Capsular gram-positive bacteria bioconjugate vaccines |
| PCT/EP2011/057111 WO2011138361A1 (en) | 2010-05-06 | 2011-05-04 | Capsular gram-positive bacteria bioconjugate vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180064T1 true HRP20180064T1 (hr) | 2018-02-23 |
Family
ID=44902091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180064TT HRP20180064T1 (hr) | 2010-05-06 | 2011-05-04 | Cjepiva s kapsularnim biokonjugatima iz gram-pozitivnih bakterija |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8871491B2 (enExample) |
| EP (2) | EP2566507B1 (enExample) |
| JP (2) | JP6339366B2 (enExample) |
| KR (2) | KR20130063510A (enExample) |
| CN (1) | CN103079591B (enExample) |
| AU (2) | AU2011249839B2 (enExample) |
| CA (1) | CA2798381C (enExample) |
| CY (1) | CY1119895T1 (enExample) |
| DK (1) | DK2566507T3 (enExample) |
| ES (2) | ES2844596T3 (enExample) |
| HR (1) | HRP20180064T1 (enExample) |
| HU (1) | HUE037956T2 (enExample) |
| IL (1) | IL222711B (enExample) |
| LT (1) | LT2566507T (enExample) |
| NO (1) | NO2566507T3 (enExample) |
| PL (1) | PL2566507T3 (enExample) |
| PT (1) | PT2566507T (enExample) |
| SG (1) | SG185433A1 (enExample) |
| SI (1) | SI2566507T1 (enExample) |
| WO (1) | WO2011138361A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60303591T2 (de) * | 2002-03-07 | 2007-03-01 | Eidgenössische Technische Hochschule Zürich | System und methode zur herstellung von rekombinanten, glykosylierten protein in prokaryontischen wirtszellen |
| PT2257307T (pt) | 2008-02-20 | 2018-10-22 | Glaxosmithkline Biologicals Sa | Bioconjugados preparados a partir de proteínas n-glicosiladas recombinantes de células procariotas |
| DK2501406T3 (en) * | 2009-11-19 | 2018-02-26 | Glaxosmithkline Biologicals Sa | BIOSYNTHESE SYSTEM PRODUCING IMMUNOGENIC POLYSACCHARIDES IN PROCARYOTIC CELLS |
| US9526775B2 (en) | 2012-04-27 | 2016-12-27 | Washington University | Glycoengineered outer membrane vesicles and use thereof as vaccines |
| JP2015522692A (ja) | 2012-07-16 | 2015-08-06 | ファイザー・インク | 糖およびその使用 |
| JP6373836B2 (ja) | 2012-07-26 | 2018-08-15 | ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド | 多量体融合タンパク質ワクチン及び免疫療法 |
| CN104837984A (zh) | 2012-10-12 | 2015-08-12 | 格林考瓦因有限公司 | 宿主细胞修饰方法 |
| CA2889767C (en) | 2012-11-07 | 2021-09-21 | Glycovaxyn Ag | Production of recombinant vaccine in e. coli by enzymatic conjugation |
| EP2946010B1 (en) | 2013-01-18 | 2018-08-29 | London School of Hygiene and Tropical Medicine | Glycosylation method |
| GB201301085D0 (en) * | 2013-01-22 | 2013-03-06 | London School Hygiene & Tropical Medicine | Glycoconjugate Vaccine |
| WO2015052344A1 (en) * | 2013-10-11 | 2015-04-16 | Glycovaxyn Ag | Methods of host cell modification |
| MX370488B (es) * | 2013-12-04 | 2019-12-16 | Glaxosmithkline Biologicals Sa | Prevencion de infecciones por staphylococcus aureus mediante vacunas de glucoproteina sintetizadas en escherichia coli. |
| EP3131577B1 (en) * | 2014-04-17 | 2020-04-22 | GlaxoSmithKline Biologicals S.A. | Modified host cells and uses thereof |
| SG11201700325SA (en) | 2014-08-08 | 2017-02-27 | Glycovaxyn Ag | Modified host cells and hybrid oligosaccharides for use in bioconjugate production |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| US10500261B2 (en) | 2014-11-05 | 2019-12-10 | The United States Of America As Represented By The Secretary Of The Navy | Synthetic antigen constructs against campylobacter jejuni |
| EP3215226A4 (en) | 2014-11-05 | 2018-05-30 | The United States Of America As Represented By The Secretary Of The Navy | Synthetic antigen constructs against campylobacter jejuni |
| WO2016107819A1 (en) | 2014-12-30 | 2016-07-07 | Glycovaxyn Ag | Compositions and methods for protein glycosylation |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| MX2017016858A (es) * | 2015-07-01 | 2018-04-30 | Glaxosmithkline Biologicals Sa | Composiciones inmunogenicas. |
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| GB201712678D0 (en) | 2017-08-07 | 2017-09-20 | Glaxosmithkline Biologicals Sa | Process for the manipulation of nucleic acids |
| GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| GB201721582D0 (en) * | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| CN108330142B (zh) * | 2018-02-09 | 2021-09-17 | 河北科技师范学院 | 一种具有免疫保护作用的美人鱼发光杆菌溶血素Hlych蛋白 |
| GB201802339D0 (en) * | 2018-02-13 | 2018-03-28 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| CN109400704B (zh) * | 2018-11-14 | 2020-07-21 | 珠海泰诺麦博生物技术有限公司 | 一种抗金黄色葡萄球菌α-溶血素的抗体及其应用 |
| JP7551618B2 (ja) * | 2018-12-12 | 2024-09-17 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Ｏ－結合型グリコシル化のための修飾キャリアタンパク質 |
| CN113646438A (zh) * | 2019-01-11 | 2021-11-12 | 西北大学 | 在原核生物细胞裂解物中合成生物缀合物疫苗 |
| EP3757217A1 (en) | 2019-06-27 | 2020-12-30 | GlaxoSmithKline Biologicals S.A. | Methods for protein purification |
| EP3770269A1 (en) | 2019-07-23 | 2021-01-27 | GlaxoSmithKline Biologicals S.A. | Quantification of bioconjugate glycosylation |
| CA3149430A1 (en) | 2019-08-09 | 2021-02-18 | Glaxosmithkline Biologicals Sa | Mutated pglb oligosaccharyltransferase enzymes |
| EP3777884A1 (en) | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| CN112575041B (zh) * | 2019-09-30 | 2022-12-13 | 江南大学 | 一种混合碳源高效发酵生产phb的工程菌及其应用 |
| BR112022023234A2 (pt) * | 2020-06-25 | 2023-01-03 | Glaxosmithkline Biologicals Sa | Proteínas de exotoxina a modificada |
| CN114085255B (zh) * | 2020-08-24 | 2023-08-29 | 山东大学 | 一种苏黎世克罗诺杆菌5型脂多糖o-抗原寡糖片段及其制备方法与应用 |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| WO2022171679A2 (en) | 2021-02-11 | 2022-08-18 | Glaxosmithkline Biologicals Sa | Protein |
| WO2023118033A1 (en) | 2021-12-22 | 2023-06-29 | Glaxosmithkline Biologicals Sa | Vaccine |
| CN117940555B (zh) * | 2022-06-30 | 2025-05-30 | 上海羽冠生物技术有限公司 | 荚膜减少的活细菌菌株 |
| GB202302579D0 (en) | 2023-02-23 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| WO2025032535A2 (en) | 2023-08-09 | 2025-02-13 | Glaxosmithkline Biologicals Sa | Modified proteins |
| WO2025032534A2 (en) | 2023-08-09 | 2025-02-13 | Glaxosmithkline Biologicals Sa | Modified proteins |
| CN117771264B (zh) * | 2023-11-27 | 2024-06-25 | 山东省农业科学院畜牧兽医研究所 | circHIF1α在制备抵御细菌感染的新型疫苗中的应用 |
| WO2025172892A1 (en) | 2024-02-16 | 2025-08-21 | Glaxosmithkline Biologicals Sa | Modified proteins and methods |
| CN120005900B (zh) * | 2025-01-21 | 2026-01-06 | 浙江大学 | FaCP5L1和FaCP5L3基因及其在调控果实成熟和采后保鲜品质中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1900A (en) | 1840-12-14 | Machine for extracting stumps | ||
| ATE67786T1 (de) | 1984-08-01 | 1991-10-15 | Boehringer Ingelheim Int | Neue genetische sequenzen, die durch sie codierten interferon-peptide vom typ i und diese sie produzierende organismen. |
| US5643758A (en) | 1987-03-10 | 1997-07-01 | New England Biolabs, Inc. | Production and purification of a protein fused to a binding protein |
| EP0726318A1 (en) | 1993-05-14 | 1996-08-14 | The Upjohn Company | An acceptor polypeptide for an N-acetylgalactosaminyltransferase |
| US6503744B1 (en) | 1999-02-01 | 2003-01-07 | National Research Council Of Canada | Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics |
| EP1399538A2 (en) | 1999-03-02 | 2004-03-24 | Human Genome Sciences, Inc. | Engineering intracellular sialylation pathways |
| HUP0302299A2 (hu) | 2000-05-12 | 2003-10-28 | Neose Technologies, Inc. | Rekombináns glikopeptidek glikozilezési mintázatának in vitro módosítása |
| MXPA02012688A (es) | 2000-06-30 | 2004-09-10 | Flanders Interuniversity Inst | Modificacion de glicosilacion de proteina en pichia pastoris. |
| US20040265954A1 (en) | 2002-03-07 | 2004-12-30 | Markus Aebi | System and method for the production of recombinant proteins |
| DE60303591T2 (de) | 2002-03-07 | 2007-03-01 | Eidgenössische Technische Hochschule Zürich | System und methode zur herstellung von rekombinanten, glykosylierten protein in prokaryontischen wirtszellen |
| AU2003254665C1 (en) | 2002-08-01 | 2010-08-19 | National Research Council Of Canada | Campylobacter glycans and glycopeptides |
| EP2657251B1 (en) | 2004-05-24 | 2018-03-21 | The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services | Live, oral vaccine for protection against Shigella dysenteriae serotype 1 |
| ES2535084T3 (es) * | 2005-05-11 | 2015-05-05 | Eth Zurich | Proteínas N-glicosiladas recombinantes procedentes de células procariotas |
| EA020459B1 (ru) | 2006-03-30 | 2014-11-28 | Глаксосмитклайн Байолоджикалс С.А. | Иммуногенная композиция |
| CN102037004A (zh) * | 2008-01-08 | 2011-04-27 | 生物种属学股份公司 | 使用寡糖基转移酶的多肽的糖缀合 |
| PT2257307T (pt) | 2008-02-20 | 2018-10-22 | Glaxosmithkline Biologicals Sa | Bioconjugados preparados a partir de proteínas n-glicosiladas recombinantes de células procariotas |
-
2011
- 2011-05-04 CA CA2798381A patent/CA2798381C/en active Active
- 2011-05-04 DK DK11724567.0T patent/DK2566507T3/da active
- 2011-05-04 PT PT117245670T patent/PT2566507T/pt unknown
- 2011-05-04 KR KR1020127031847A patent/KR20130063510A/ko not_active Ceased
- 2011-05-04 HU HUE11724567A patent/HUE037956T2/hu unknown
- 2011-05-04 US US13/100,603 patent/US8871491B2/en active Active
- 2011-05-04 SI SI201131403T patent/SI2566507T1/en unknown
- 2011-05-04 ES ES17192866T patent/ES2844596T3/es active Active
- 2011-05-04 CN CN201180033560.1A patent/CN103079591B/zh not_active Expired - Fee Related
- 2011-05-04 HR HRP20180064TT patent/HRP20180064T1/hr unknown
- 2011-05-04 PL PL11724567T patent/PL2566507T3/pl unknown
- 2011-05-04 EP EP11724567.0A patent/EP2566507B1/en active Active
- 2011-05-04 EP EP17192866.6A patent/EP3281639B1/en active Active
- 2011-05-04 ES ES11724567.0T patent/ES2657588T3/es active Active
- 2011-05-04 AU AU2011249839A patent/AU2011249839B2/en not_active Ceased
- 2011-05-04 JP JP2013508489A patent/JP6339366B2/ja not_active Expired - Fee Related
- 2011-05-04 SG SG2012081535A patent/SG185433A1/en unknown
- 2011-05-04 NO NO11724567A patent/NO2566507T3/no unknown
- 2011-05-04 WO PCT/EP2011/057111 patent/WO2011138361A1/en not_active Ceased
- 2011-05-04 LT LTEP11724567.0T patent/LT2566507T/lt unknown
- 2011-05-04 KR KR1020187004586A patent/KR101916290B1/ko not_active Expired - Fee Related
-
2012
- 2012-10-25 IL IL222711A patent/IL222711B/en active IP Right Grant
-
2014
- 2014-09-23 US US14/494,150 patent/US9585950B2/en not_active Expired - Fee Related
-
2016
- 2016-07-25 AU AU2016208265A patent/AU2016208265A1/en not_active Abandoned
- 2016-10-06 JP JP2016197813A patent/JP6435583B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-25 US US15/414,900 patent/US10307473B2/en active Active
-
2018
- 2018-02-06 CY CY20181100148T patent/CY1119895T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180064T1 (hr) | Cjepiva s kapsularnim biokonjugatima iz gram-pozitivnih bakterija | |
| HRP20160276T1 (hr) | Pripravci za imuniziranje protiv bakterije staphylococcus aureus | |
| WO2011110655A3 (en) | Immunogenic composition or vaccine against gram - negative bacterial, for example neiserial, infection or disease | |
| WO2018089851A3 (en) | Influenza vaccine | |
| WO2015024668A3 (en) | Respiratory syncytial virus (rsv) vaccine | |
| WO2008073891A3 (en) | Salmonella vaccine in poultry | |
| DK2707393T3 (da) | Fusionsproteiner og kombinationsvacciner omfattende haemoph-ilus influenzae-protein e og pilin a | |
| CO2021001926A2 (es) | Composiciones de escherichia coli y métodos de estas | |
| HRP20181102T1 (hr) | Cjepiva za hsv-2 | |
| WO2011004263A3 (en) | Conserved escherichia coli immunogens | |
| HRP20190907T1 (hr) | Imunogeni pripravak koji sadrži polipeptide iz panton-valentin leukocidina (pvl) | |
| JP2016522259A5 (enExample) | ||
| CO6670521A2 (es) | Vacuna y m´todos para reducir una infección por campylobacter | |
| WO2017214596A8 (en) | Compositions and methods for preventing and treating zika virus infection | |
| HRP20241279T1 (hr) | Pripravak koji sadrži probiotike koji prekomjerno eksprimiraju protein clpb za uporabu u liječenju pretilosti | |
| WO2011025344A3 (ko) | 소의 병원성 대장균의 부착인자가 형질전환된 약독화 살모넬라균 변이주 및 이를 포함하는 소의 대장균증 및 살모넬라균증의 예방 및 치료용 백신조성물 | |
| BRPI1014505A8 (pt) | Proteína de fusão de múltiplos epítopos, método para produzir uma composição, polinucleotídeo, vetor recombinante, célula hospedeira, método para produzir uma proteína de fusão de múltiplos epítopos, kit de teste imunodiagnóstico, composição, e, uso de uma proteína de fusão de múltiplos epítopos | |
| HRP20180039T1 (hr) | Antigeni pseudomonasa i kombinacije antigena | |
| HRP20191864T1 (hr) | Imunogeni pripravci protiv bakterije clostridium difficile | |
| HN2010000718A (es) | Proteina m de estreptococo, fragmentos inmunogenicos,acidos nucleicos y metodos de uso. | |
| WO2010046778A3 (en) | Novel shigella frotein antigens and methods | |
| WO2009014382A3 (en) | Cxcl11 adjuvant compositions and uses thereof | |
| WO2011009771A3 (en) | Immunogenic and therapeutic compositions for streptococcus suis | |
| EP3586871A3 (en) | Respiratory syncytial virus (rsv) vaccine | |
| Kumar et al. | Comparative immune response of purified native OmpH protein derived from Pasteurella multocida P52 and oil adjuvant vaccine against hemorrhagic septicemia in mice |